Edition:
United Kingdom

Blueprint Medicines Corp (BPMC.OQ)

BPMC.OQ on NASDAQ Stock Exchange Global Select Market

69.61USD
21 Sep 2018
Change (% chg)

-- (--)
Prev Close
$69.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
141,690
52-wk High
$108.62
52-wk Low
$57.51

Latest Key Developments (Source: Significant Developments)

Blueprint Medicines Reports Q2 Loss Per Share $0.62
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.62.Q2 EARNINGS PER SHARE VIEW $-1.32 -- THOMSON REUTERS I/B/E/S.BLUEPRINT MEDICINES - EXPECTS EXISTING CASH, CASH EQUIVALENTS, INVESTMENTS SUFFICIENT TO ENABLE IT TO FUND OPERATING EXPENSES & CAPEX INTO H2 2020.AS OF JUNE 30, 2018, CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $616.7 MILLION, VERSUS $673.4 MILLION AS OF DECEMBER 31, 2017.  Full Article

Blueprint Medicines Prices Public Offering Of 3.70 Mln Shares At $81.00/Share
Wednesday, 13 Dec 2017 

Dec 12 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.70 MILLION COMMON SHARES PRICED AT $81.00PER SHARE.  Full Article

Blueprint Medicines Announces Proposed Public Offering Of Shares Of Common Stock
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK.BLUEPRINT MEDICINES CORP SAYS IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $275.0 MILLION IN SHARES OF ITS COMMON STOCK.BLUEPRINT MEDICINES-EXPECTS TO USE PROCEEDS OF OFFERING TO FUND CLINICAL TRIALS FOR AVAPRITINIB IN GASTROINTESTINAL STROMAL TUMORS,SYSTEMIC MASTOCYTOSIS.BLUEPRINT MEDICINES CORP SAYS ALSO EXPECTS TO USE NET PROCEEDS OF OFFERING TO FUND CLINICAL TRIALS FOR BLU-554 IN HEPATOCELLULAR CARCINOMA.BLUEPRINT MEDICINES CORP SAYS ALSO EXPECTS TO USE NET PROCEEDS OF OFFERING TO FUND CLINICAL TRIALS FOR BLU-667 IN RET-DRIVEN CANCERS.  Full Article

Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285 in patients with advanced gastrointestinal stromal tumors showing strengthened clinical activity across spectrum of kit and pdgfrα genotypes.Blueprint Medicines Corp - ‍new cohort in second-line gist added to ongoing phase 1 trial​.Blueprint Medicines Corp - ‍global, randomized phase 3 trial in third-line gist on track to initiate in first half 2018​.  Full Article

Blueprint Medicines Q3 loss per share $0.96
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines reports third quarter 2017 financial results.Q3 loss per share $0.96.Q3 earnings per share view $-0.91 -- Thomson Reuters I/B/E/S.Blueprint Medicines - ‍existing cash will be sufficient to fund its operating expenses and capex requirements into H2 2019​.Blueprint Medicines - ‍plans to initiate a global, pivotal Phase 3 clinical trial of BLU-285 in third-line patients with KIT-driven GIST in H1 2018​.  Full Article

James Flynn reports 4.51 pct passive stake in Blueprint Medicines
Tuesday, 25 Oct 2016 

Blueprint Medicines Corp :James Flynn reports 4.51 percent passive stake in Blueprint Medicines Corp as of October 20 - sec filing.  Full Article

Loxo Oncology posts improved results for newest cancer drug

CHICAGO, June 2 An experimental cancer drug from Loxo Oncology performed even better in patients with a rare mutation of the RET gene than previously reported, according to updated results from an early stage clinical trial presented on Saturday.